Effect of piceatannol in human monocyte-derived dendritic cells in vitro

Journal of Pharmaceutical Sciences

Volumn 94, Issue 5, 2005, Pages 974-982

  Takei, Masao ^a   Umeyama, Akemi ^b   Arihara, Shigenobu ^b   Matsumoto, Hitoshi ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Dendritic cell; Piceatannol; Th1

Indexed keywords

ANTIINFLAMMATORY AGENT; B7 ANTIGEN; CANCER VACCINE; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PICEATANNOL; STILBENE; T6 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; ENDOCYTOSIS; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 20344377385     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20279     Document Type: Article

References (35)

1. Bhat KP, Pezzuto JM. 2002. Cancer chemopreventive activity of resveratrol. Ann NY Acad Sci 957: 210-229.
2. Ferrigni NR, Mclaughin JL, Powell RG, Smith C. 1984. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the anti-leukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 47:347-356.
3. Wieder T, Prokop B, Essmann F, Bernicke D, Schulze-Osthoff K, Dorken B, Schmalz HG, Daniel PT, Henze G. 2001. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15:1735-1742.
4. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. 2002. Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol 169:6490-6497.
5. Mellman I, Steinman RM. 2001. Dendritic cells: Specialized and regulated antigen processing machines. Cell 106:2555-2562.
6. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 106: 245-252.
7. Lanzavecchia A, Sallusto AF. 2001. Regulation of T cell immunity by dendritic cells. Cell 106:263-266.
8. Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M. 2000. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or TH1/Th2 effectors: Role of stimulator/responder ratio. J Exp Med 192:405-411.
9. Tao X, Grant C, Constant S, Bottomly K. 1997. Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR binding. J Immunol 158:4237-4244.
10. Iezzi G, Scotet E, Scheidegger D, Lanzavecchia A. 1999. The interplay between the duration of TCR and cytokine signalling determines T cell polarization. Eur J Immunol 29:4092-4101.
11. Kuchroo VK, Dasa MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: Application to autoimmune disease therapy. Cell 80:707-713.
12. Lederer JA, Perez VL, Desroches L, Kim SM, Abbas AK, Lichtman AH. 1996. Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med 84:397-406.
13. Romagnani S. 1994. Lymphokine production by human T cells in disease state. Annu Rev Immunol 12:227-257.
14. O'grra A. 2001. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275-278.
15. Trinchieri G, Scott P. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 15:460-463.
16. O'garra A, Murphy K. 1993. T-cell subsets in autoimmunity. Curr Opin 5:880-886.
17. Fong L, Engleman EG. 2000. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273.
18. Medzhitov R, Preston-Hurlburt P, Janeway CA. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394-399.
19. Grage-Griebenow E, Lorenzen D, Fetting R, Flad HD, Ernst M. 1993. Phenotypical and functional characterisation of FCγ receptor 1 (CD64)-negative Mo, a minor human monocyte subpopulation with high accessory and antiviral activity. Eur J Immunol 23:3126-3131.
20. Lee JJ, Takei M, Hori S, Inoue Y, Takaue Y. 2002. The role of PGE2 in the differentiation of dendritic cells; How do dendritic cells influence T-cell polarization and chemokine receptor expression? Stem Cells 20:448-459.
21. Delespesse G, Ohshima Y, Shu U, Yang L-P, Demeure C, Wu C-Y, Byun D-G, Sarfat M. 1997. Differentiation of naïve human CD4 T cells into Th2/Th1 effectors. Allergol Int 46:63-72.
22. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. 2000. Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells. Nat Immunol 1:311-315.
23. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. 1998. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 16:495-521.
24. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'garra A, Murphy KM. 1993. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549.
25. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U. 1998. The interleukin-12/ interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 16:495-521.
26. Shurin MR, Kalinski P, Stewart-Akers M, Lotze MT. 1999. Th1/Th2 balance in cancer, transplantation pregnancy. Springer Semin Immunopathol 21: 339-359.
27. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. 1993. Tumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 78: 1223-1226.
28. Salio M, Cerudolo V, Lanzavecchia A. 2000. Dendritic cell maturation is induced by mycoplasma infection but not necrotic cells. Eur J Immunol 30:705-712.
29. Matsuda H, Kageura T, Morikawa T, Toguchida I, Harima S, Yoshikawa M. 2000. Effects of stilbene constitutes from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages. Bioorg Med Chem Lett 10:323-326.
30. Bhat KP, Kosmeder JW Jr, Pezzuto JM. 2001. Biological effects of resveratrol. Antitoxid Redox Signalling 3:1041-1048.
31. Kim G-Y, Cho H, Ahn S-C, Of Y-H, Lee C-M, Park Y-M. 2004. Resveratrol inhibits phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int Immunopharmacol 4: 245-253.
32. Okumoto M, Sato M. 2003. Toll-like receptor signalling in anti-cancer immunity. J Med Invest 50:9-24.
33. Radolf JD, Arndt LL, Akins DR, Curetty LL, Levi ME, Shen Y, Davis LS, Norgard MV. 1995. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytes/ macrophages. J Immunol 154:2866-2877.
34. Thoma-Usynski SS, Kiertscher SM, Ochoa MT, Bouis DA, Norgard MV, Miyake K, Godowski PJ, Roth MD, Modlin RL. 2000. Activation of Toll-like receptor 2 on human dendritic cells triggers induction of IL-12 but not IL-10. J Immunol 165: 3804-3810.
35. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S. 2002. Role of TLR1 in mediating immune response to microbial lipoproteins. J Immunol 169:10-14.